adrenoleukodystrophy ald disease linked x chromosome result fatty acid buildup caused failure peroxisomal fatty acid beta oxidation results accumulation long chain fatty acids tissues throughout body severely affected tissues myelin central nervous system adrenal cortex leydig cells testes long chain fatty acid buildup causes damage myelin sheath neurons brain resulting seizures hyperactivity symptoms include problems speaking listening understanding verbal instructions clinically ald presents heterogeneous disorder showing several distinct phenotypes clear pattern correlation xlinked disorder ald presents commonly males however approximately heterozygote females show symptoms later life approximately twothirds ald patients present childhood cerebral form disease severe form characterized normal development early childhood followed rapid degeneration vegetative state forms ald vary timing onset clinical severity ranging adrenal insufficiency alone progressive paraparesis early adulthood ald caused mutations gene located x chromosome codes ald peroxisomal membrane transporter protein exact mechanism pathogenesis various forms ald known biochemically individuals ald show high levels unbranched saturated long chain fatty acids particularly cerotic acid level cerotic acid plasma correlate clinical presentation treatment options ald limited childhood cerebral form stem cell transplant gene therapy options disease detected early clinical course adrenal insufficiency ald patients successfully treated ald common peroxisomal inborn error metabolism incidence estimated significantly higher incidence specific ethnic group ald present different ways different presentations complicated pattern xlinked recessive inheritance seven phenotypes described males mutations five initial symptoms boys affected childhood cerebral form ald include emotional instability hyperactivity disruptive behavior school older patients affected cerebral form present similar symptoms untreated cerebral ald characterized progressive demyelination leading vegetative state adult males adrenomyeloneuropathy presentation typically present initially muscle stiffness paraparesis sexual patients clinically recognized ald phenotypes risk adrenal reliable way predict form disease affected individual develop multiple phenotypes demonstrated within onset adrenal insufficiency often first symptom appearing early two years ald caused mutations located demonstrates xlinked recessive inheritance gene encodes peroxisomal membrane transporter responsible transporting long chain fatty acid substrate peroxisomes mutations gene interfere process cause syndromecitation needed males mutation hemizygous single x chromosome female carriers typically avoid severe manifestations disease often become symptomatic later although detection mutation identifies individual affected form ald within family often several different phenotypes despite presence causative mutation one case family six affected members displayed five different common mutations cause ald private familial almost different mutations identified approximately half missense mutations one quarter frameshifts inframe deletions splicing defects making incidence new mutations ald occurring spontaneously rather inherited carrier parent estimated possibility due germline exact cause varied collection symptoms found different ald phenotypes clear white matter brain leydig cells testes adrenal cortex severely affected excess vlcfa detected almost tissues body despite localization lack coenzyme permit disintegration vlcfa accumulating white matter adrenal glands testes specifically leydig cells allowing proper function organs successful treatment demyelination process affects brain either stem cell transplant gene therapy immediately normalize vlcfa levels body levels vlcfa normalized treatment lorenzos oil alter progression unclear whether accumulation vlcfa associated pathogenesis disease specific way biochemical phenotype useful clinical presentation ald vary greatly making diagnosis difficult variety phenotypes clinical suspicion ald result variety different presentations symptoms vary based disease phenotype even within families ald suspected based clinical symptoms initial testing usually includes plasma long chain fatty acid vlcfa determination using gas chromatographymass spectrometry concentration unsaturated vlcfa particularly carbon chains significantly elevated males ald even prior development confirmation ald positive plasma vlcfa determination usually involves molecular genetic analysis females plasma vlcfa measurement always conclusive female carriers normal vlcfa molecular analysis preferred particularly cases mutation family although clinical phenotype highly variable among affected males elevations vlcfa present males characteristic elevations associated ald present birth well symptoms apparent methods interests including newborn screening one difficulties ald disease included universal newborn screening difficulty predicting eventual phenotype individual express accepted treatment affected boys presenting cerebral childhood form disease bone marrow transplant procedure carries significant however affected males demonstrate adrenal insufficiency early discovery treatment symptom could potentially prevent complications allow patients monitored treatment future depending progression loes score rating severity abnormalities brain found mri ranges based point system derived location extent disease presence atrophy brain either localized specific points generally throughout brain loes score less classified normal loes score greater considered severe developed neuroradiologist daniel j loes md important tool assessing disease progression effectiveness initial attempts dietary therapy ald involved restricting intake verylong chain fatty acids vlcfa dietary intake source vlcfa body also synthesized endogenously dietary restriction impact levels vlcfa plasma body realization endogenous synthesis important contribution vlcfa body efforts dietary therapy shifted inhibiting synthetic pathways body parents lorenzo odone boy ald spearheaded efforts develop dietary treatment slow progression disease developed mixture unsaturated fatty acids glycerol trioleate glyceryl trierucate ratio known lorenzos oil inhibits elongation saturated fatty acids supplementation lorenzos oil found normalize vlcfa concentrations body although effectiveness treating cerebral manifestations disease still controversial trials lorenzos oil shown stop neurological degradation symptomatic patients improve adrenal asymptomatic patients speculatively amn variants without cerebral involvement well female carriers may benefit early intake oleic erucic acids addition vlcfa secondgeneration mixture created adding glycerol trioleate gto trierucate glycerol gte conjugated linoleic acid cla group linoleic acid isomers capable overcoming bloodbrain barrier cla activation peroxisome beta oxidation increases catabolism proinflammatory molecules ros acting antiinflammatory antioxidant use cla initially considered relation ability inhibit fatty acid synthase together hypolipidic diet group italian researchers bambino gesù pediatric hospital rome showed administration adrenomix gto gte cla addition decreasing levels vlcfa throughout body reduces neuro inflammation improves somatosensory evoked potential found unchanged worsened administration gto based studies developed recent years field adrenoleukodystrophy adrenomyelouropathy mixture developed adds gto gte cla mixture powerful antioxidants high dosages containing alpha lipoic acid ala reduced l glutathione vitamin e α tocopherol researchers idibell hospital duran reynals barcelona shown early administration cocktail powerful antioxidants able overcome bloodbrain barrier thus carry activity cns level prevents oxidative stress typical disease intervenes initial axonal dysfunctions therefore locomotor new mixture unlike happened administration gto gte alone poorly accumulated level nervous system enhances antiinflammatory activity reduces levels vlcfa cns combining synergistically activity components particular cla addition overcoming bloodbrain barrier regulating cns level metabolism vlcfa able influence catabolism proinflammatory eicosanoids lipid peroxidation sense antiinflammatory activity ala reduced lglutathione vitamin e enhanced level whole body peripheral level case dietary therapy shown effective normalize verylong chain fatty acid concentrations plasma individuals ald allogeneic hematopoietic stem cell transplants treatment stop demyelination hallmark cerebral forms order effective transplant must done early stage disease demyelination progressed transplant worsen outcome increase rate decline transplants shown effective halting demyelination process presenting childhood cerebral form ald followup patients shown improve adrenal patients appropriate match transplant found investigations use gene therapy appropriate vectors selected modified express wild type transplanted patients using similar procedure bone marrow stem cell gene therapy tried small number patients mainly france patients considered gene therapy hla match traditional transplant two reported cases gene therapy successful resolution demyelination process two years procedure although gene therapy successful resolving neurological symptoms plasma vlcfa levels remained elivaldogene autotemcel pending authorization european commission may treatment effective patients free major functional disabilities treatment costs million per treatment comes several adverse effects including mucositis alopecia treatment adrenal insufficiency accompany common male phenotypes ald resolve neurological symptoms hormone replacement standard ald patients demonstrating adrenal adrenal insufficiency resolve successful transplant patients still require hormone ald shown increased incidence specific country ethnic group united states incidence affected males estimated overall incidence hemizygous males carrier females estimated reported incidence france estimated documented asymptomatic males present ald symptoms well understood gene variant possess elevated vlcfas exhibit either cerebral ald adrenal insufficiency adrenomyeloneuropathy symptoms daughters asymptomatic males become obligate carriers may asymptomatic pass variant onto children silently perpetuates ald sons asymptomatic males receive fathers chromosome therefore cant inherit httpsenwikipediaorgwikiadrenoleukodystrophy